Loading...
MTAA
DIA
Market cap3.91bUSD
Jun 18, Last price  
63.74EUR
1D
-1.27%
1Q
-0.03%
Jan 2017
13.32%
IPO
432.94%
Name

DiaSorin SpA

Chart & Performance

D1W1MN
MTAA:DIA chart
P/E
18.13
P/S
2.88
EPS
3.52
Div Yield, %
1.88%
Shrs. gr., 5y
0.34%
Rev. gr., 5y
10.90%
Revenues
1.20b
+0.84%
179,756,000202,324,000244,612,000304,129,000404,547,000440,003,000433,763,000434,849,000443,770,000499,181,000569,312,000637,487,000669,197,000706,319,000881,305,0001,237,654,0001,361,138,0001,148,210,0001,185,000,0001,195,000,000
Net income
156m
-17.27%
22,294,00025,219,00037,459,00070,047,00090,418,00099,607,00087,396,00083,028,00084,074,000100,420,000112,383,000139,878,000158,128,000175,735,000247,871,000310,968,000240,907,000159,849,000188,105,000155,624,000
CFO
343m
-4.47%
33,976,00030,348,00047,779,00064,219,00095,791,000108,578,000110,582,000107,717,000119,847,000138,449,000165,597,000167,440,000209,879,000232,670,000304,562,000400,664,000389,341,000311,663,000358,782,000342,760,000
Dividend
May 19, 20251.2 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

DiaSorin S.p.A. specializes in the creation, production, and global distribution of both immunodiagnostic and molecular diagnostic testing kits. Their extensive reach covers Europe, Africa, North, Central, and South America, the Asia Pacific region, and China. The company's offerings include a suite of immunodiagnostic LIAISON platforms, such as the LIAISON XS, LIAISON XL, and LIAISON XL LAS. For molecular diagnostics, they provide the LIAISON MDX system, which is utilized for amplifying nucleic acids to identify viruses in patient samples, thereby enabling the diagnosis of viral infections. DiaSorin has also established key collaborations: a partnership with QIAGEN focuses on a diagnostic solution for latent tuberculosis detection; another with TTP is for advancing molecular Point-of-Care solutions; and a third with MeMed aims to introduce a test capable of distinguishing between viral and bacterial infections. This enterprise, established in 1968, has its corporate headquarters situated in Saluggia, Italy.
IPO date
Jul 19, 2007
Employees
3,278
Domiciled in
IT
Incorporated in
IT

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT